Rein Therapeutics Inc (RNTX) Stock Price, Quote & News

Company Profile

Rein Therapeutics Inc., a biopharmaceutical company, focuses on developing medicines to address unmet medical needs in orphan pulmonary and fibrosis indications in the United States. The company's lead product candidate is LTI-03, a peptide, which is in Phase 1b clinical trial for the treatment of idiopathic pulmonary fibrosis (IPF). It also offers LTI-01, a proenzyme that has completed Phase 1b and Phase 2a clinical trials in LPE patients for the treatment of loculated pleural effusion. The com...

Industry: Biotechnology

Sector: Healthcare

Phone: 737 802 1989

Website: www.reintx.com

Address:

12407 N. Mopac Expy., Suite 250 #390, Austin, United States

PenkeTrading Jun. 24 at 5:18 AM

I found you an Oversold RSI (Relative Strength Index) on the daily chart of Rein Therapeutics Inc. Is that bullish or bearish? $RNTX #Rein #RsiOversold #NASDAQ

0 · Reply

Klinsmann Jun. 3 at 4:20 PM

$RNTX starter

0 · Reply

BlackPillOverdose May. 29 at 3:01 PM

$RNTX why no

0 · Reply

Market Cap	34.12M
Revenue (ttm)	0.00
Net Income (ttm)	-62.88M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	41,000
Avg Vol	37,924
Day's Range	N/A - N/A
Shares Out	22.15M
Stochastic %K	14%
Beta	1.30
Analysts	Strong Sell
Price Target	$7.00

Rein Therapeutics Inc (RNTX)

Company Profile

Rein Therapeutics Announces Adjournment of Annual Meeting of Stockholders

US FDA puts on hold Rein Therapeutics' lung disease drug trial

Rein Therapeutics Announces First Patient Dosed in RENEW Phase 2 Trial of LTI-03 in Patients with IPF

Rein Therapeutics Presents Two Posters at the American Thoracic Society 2025 International Conference

Rein Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update

Rein Therapeutics Announces Initiation of RENEW Phase 2 Trial of LTI-03 in Patients with IPF

Rein Therapeutics and Qureight Ltd Announce Planned Integration of Deep-Learning Platform for Phase 2 Trial of LTI-03 in Patients with IPF

Rein Therapeutics to Present at The Citizens Life Sciences Conference 2025

Rein Therapeutics Announces Abstract Accepted for Presentation at the American Thoracic Society 2025 International Conference

Rein Therapeutics Granted Two Patents Covering the Novel Formulation and Administration Methods of Dry Powder LTI-03 for the Treatment of Respiratory Diseases

Rein Therapeutics Announces a Publication in Biomedicines on the Immunomodulatory and Anti-fibrotic Properties of a Caveolin-1-Related Peptide in IPF and PASC-F

Rein Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update